JP2017508467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508467A5 JP2017508467A5 JP2016555990A JP2016555990A JP2017508467A5 JP 2017508467 A5 JP2017508467 A5 JP 2017508467A5 JP 2016555990 A JP2016555990 A JP 2016555990A JP 2016555990 A JP2016555990 A JP 2016555990A JP 2017508467 A5 JP2017508467 A5 JP 2017508467A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rna molecule
- rnase
- coding chimeric
- chimeric mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 25
- 108091064355 mitochondrial RNA Proteins 0.000 claims 24
- 102100034343 Integrase Human genes 0.000 claims 21
- 101710203526 Integrase Proteins 0.000 claims 21
- 108060002716 Exonuclease Proteins 0.000 claims 14
- 102000013165 exonuclease Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 102100023387 Endoribonuclease Dicer Human genes 0.000 claims 6
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 3
- 230000002438 mitochondrial effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000000137 annealing Methods 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108020004418 ribosomal RNA Proteins 0.000 claims 2
- 108091029480 NONCODE Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953672P | 2014-03-14 | 2014-03-14 | |
| US61/953,672 | 2014-03-14 | ||
| PCT/IB2015/001233 WO2015150924A2 (en) | 2014-03-14 | 2015-03-13 | Pharmaceutical compositions comprising rna and use for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017508467A JP2017508467A (ja) | 2017-03-30 |
| JP2017508467A5 true JP2017508467A5 (enExample) | 2018-04-19 |
Family
ID=54241387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555990A Withdrawn JP2017508467A (ja) | 2014-03-14 | 2015-03-13 | がんを処置するためのｒｎａを含む医薬組成物および使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170183650A1 (enExample) |
| EP (1) | EP3116513A4 (enExample) |
| JP (1) | JP2017508467A (enExample) |
| CA (1) | CA2939860A1 (enExample) |
| WO (1) | WO2015150924A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111603477B (zh) * | 2019-02-25 | 2023-06-02 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2406169B (en) * | 2002-06-12 | 2006-11-01 | Ambion Inc | Methods and compositions relating to labeled rna molecules that reduce gene expression |
| US6975830B2 (en) * | 2002-09-12 | 2005-12-13 | Ricoh Company, Limited | Image forming apparatus, process cartridge, and waste toner recovery device |
| EP2270159B1 (en) * | 2003-05-21 | 2015-01-07 | Andes Biotechnologies S.A. | Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
| CA2647338A1 (en) * | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors-3 |
| DE102008040682A1 (de) * | 2008-07-24 | 2010-01-28 | Robert Bosch Gmbh | Sensoranordnung und Verfahren zum Betrieb einer Sensoranordnung |
| WO2012103154A1 (en) * | 2011-01-24 | 2012-08-02 | Nugen Technologies, Inc. | Stem-loop composite rna-dna adaptor-primers: compositions and methods for library generation, amplification and other downstream manipulations |
-
2015
- 2015-03-13 EP EP15772736.3A patent/EP3116513A4/en not_active Withdrawn
- 2015-03-13 WO PCT/IB2015/001233 patent/WO2015150924A2/en not_active Ceased
- 2015-03-13 US US15/125,947 patent/US20170183650A1/en not_active Abandoned
- 2015-03-13 JP JP2016555990A patent/JP2017508467A/ja not_active Withdrawn
- 2015-03-13 CA CA2939860A patent/CA2939860A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4310196A3 (en) | Methods and compositions for manipulating nucleic acids | |
| PH12018500145A1 (en) | Oligonucleotide compositions and methods thereof | |
| WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
| WO2018041973A9 (en) | Chemically modified single-stranded rna-editing oligonucleotides | |
| JP2014525921A5 (enExample) | ||
| WO2015107425A8 (en) | Chiral design | |
| WO2010141511A3 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
| JP2012228254A5 (enExample) | ||
| FI3445388T3 (fi) | Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi | |
| FI3690056T3 (fi) | Menetelmiä ja tuotteita nukleiinihapon valmistamiseksi ja viemiseksi | |
| JP2015142558A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| RU2019138705A (ru) | Транспозиция с сохранением сцепления генов | |
| JP2017537626A5 (enExample) | ||
| JP2016526529A5 (enExample) | ||
| RU2015128098A (ru) | Конструирование систем, способы и оптимизированные направляющие композиции для манипуляции с последовательностями | |
| EP4328322A3 (en) | Probe library construction | |
| WO2014092886A3 (en) | Pairing code directed assembly | |
| WO2015083001A3 (en) | Nucleic acid probe and method of detecting genomic fragments | |
| WO2012092569A3 (en) | Compositions comprising immunostimulatory nucleic acids and related methods | |
| JP2017529849A5 (enExample) | ||
| JP2012223202A5 (enExample) | ||
| AR088263A1 (es) | Moleculas de acido nucleico que se dirigen a rps6 y confieren resistencia a plagas de coleopteros | |
| JP2013046616A5 (enExample) | ||
| CN105238781B (zh) | 基于转录组序列开发的李ssr标记引物对及其应用 |